Antimuscarinics for the treatment of overactive bladder: Understanding the role of muscarinic subtype selectivity

International Urogynecology Journal

Volumn 22, Issue 8, 2011, Pages 907-917

  Glavind, Karin ^a   Chancellor, Michael ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Antimuscarinics; Cardiovascular; Cognitive function; Muscarinic; Overactive bladder; Receptor selectivity

Indexed keywords

CHOLINESTERASE INHIBITOR; DARIFENACIN; FESOTERODINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLURRED VISION; CARDIOVASCULAR EFFECT; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG WITHDRAWAL; HUMAN; MEMORY DISORDER; OVERACTIVE BLADDER; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; TREATMENT RESPONSE; XEROSTOMIA;

EID: 80052443919     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-011-1411-6     Document Type: Review

References (87)

1. Andersson KE (2002) Potential benefits of muscarinic M3 receptor selectivity. Eur Urol 1:23-28
2. Caulfield MP, Birdsall NJM (1998) International Union of Pharmacology XVII Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-290
3. Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565-578
4. Collison DJ, Coleman RA, James RS, Carey J, Duncan G (2000) Characterization of muscarinic receptors in human lens cells by pharmacologic and molecular techniques. Invest Ophthalmol Vis Sci 41:2633-2641
5. Jeon J, Dencker D, Wortwein G et al (2010) A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J Neurosci 30:2396-2405
6. Raffa RB (2009) The M5 muscarinic receptor as possible target for treatment of drug abuse. J Clin Pharm Ther 34:623-629
7. Ragozzino ME, Mohler EG, Prior M, Palencia CA, Rozman S (2009) Acetylcholine activity in selective striatal regions supports behavioral flexibility. Neurobiol Learn Mem 91:13-22
8. Tobin G, Ryberg AT, Gentle S, Edwards AV (2006) Distribution and function of muscarinic receptor subtypes in the ovine submandibular gland. J Appl Physiol 100:1215-1223
9. Chess-Williams R (2002) Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 22:133-145
10. Haylen BT, De Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 21:5-26
11. Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC (2002) M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 136:641-643
12. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein DA (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur Urol 54:543-562
13. Novara G, Galfano A, Secco S et al (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740-763
14. Ikeda K, Kobayashi S, Suzuki M et al (2002) M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 366:97-103
15. Napier C, Gupta P (2002) Darifenacin is selective for the human recombinant M3 receptor subtype [abstract 445]. Annual Meeting of the International Continence Society, Heidelberg, Germany. https://www.icsoffice. org/ASPNET-Membership/Membership/ Abstracts/AbstractsSearch.aspx?EventID=40. Accessed 7 October 2010
16. Ohtake A, Saitoh C, Yuyama H et al (2007) Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 30:54-58
17. Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stohr T, Andersson KE (2008) Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 101:1036-1042
18. Wiedemann A, Schwantes PA (2007) Antimuscarinic drugs for the tretment of overactive bladder: are they really the same? - A comparative review of data pertaining to pharmacological and physiological aspects. Euro J Geriatr 9(Suppl 1):29-42
19. Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC Study. Eur Urol 50:1306-1314
20. Stewart W, Herzog R, Wein A et al (2001) Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 20:406-408
21. Garnett S, Swithinbank L, Ellis-Jones J, Abrams P (2009) The long-term natural history of overactive bladder symptoms due to idiopathic detrusor overactivity in women. BJU Int 104:948-953
22. Crook TH, Lebowitz BD, Pirozzolo FJ et al (1993) Recalling names after introduction: changes across the adult life span in two cultures. Dev Neuropsychol 9:103-113
23. Shi S, Morike K, Klotz U (2008) The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 64:183-199
24. Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS (2009) Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 106:268-274
25. Kay G, Granville LJ (2005) Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 27:127-138
26. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff JW, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760-766
27. Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B (2011) Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 56:7-18
28. Zinner N, Tuttle J, Marks L (2005) Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 23:248-252
29. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987-1006
30. Kay GG, Ebinger U (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62:1792-1800
31. Olshansky B, Spierings E, Brum J, Mongay L, Egermark M, Seifu Y (2009) Validation of the differential cardiovascular effects of the antimuscarinic agents, darifenacin and tolterodine, in a randomized, placebo-controlled, 3-way crossover study. UroToday Int J 2
32. Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L (2008) Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, doubleblind, cross-over study with tolterodine and darifenacin in healthy participants > or =50 years old. J Cardiovasc Pharmacol Ther 13:241-251
33. Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L (2009) Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 15:S118-S122
34. Benner JS, Nichol MB, Rovner ES et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276-1282
35. DuBeau CE (2007) Treatment of OAB in geriatric patients. Clin Geriatr 15(Suppl 2):4-6
36. Katz G, Lazcano-Ponce E (2008) Intellectual disability: definition, etiological factors, classification, diagnosis, treatment and prognosis. Salud Pública Méx 50(Suppl 2):s132-s141
37. McGrother CW, Donaldson MM, Hayward T, Matthews R, Dallosso HM, Hyde C (2006) Urinary storage symptoms and comorbidities: a prospective population cohort study in middleaged and older women. Age Ageing 35:16-24
38. Fowler CJ, Panicker JN, Drake M et al (2009) A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 85:552-559
39. de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B (2007) The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 13:915-928
40. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168:508-513
41. Kay G (2007) Anticholinergic therapy for OAB: Cognitive implications for an at-risk geriatric population. Clin Geriatr 15 (Suppl 2):10-13
42. Merchant RA, Li B, Yap KB, Ng TP (2009) Use of drugs with anticholinergic effects and cognitive impairment in communityliving older persons. Age Ageing 38:105-108
43. Isik AT, Celik T, Bozoglu E, Doruk H (2009) Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 13:672-676
44. Geyer J, Gavrilova O, Petzinger E (2009) The role of pglycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 37:1371-1374
45. Malhotra B, Wood N, Sachse R, Gandelman K (2008) Lipophilicity of 5-hydroxymethyl tolterodine, the active metabolite of fesoterodine. UroToday Int J 1
46. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC (2009) The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 16:4481-4489
47. Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colon R (2006) Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther 28:1247-1272
48. Michel MC (2008) Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 9:1787-1796
49. Devineni D, Skerjanec A, Woodworth TG (2005) Low central nervous system (CNS) penetration by darifenacin in rats. AAPS J 7:T2277 (abstract)
50. Påhlman I, d'Argy R, Nilvebrant L (2001) Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. Arzneimittelforschung 51:125-133
51. Yoshida A, Maruyama S, Fukumoto D, Tsukada H, Ito Y, Yamada S (2010) Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. Life Sci 87:175-180
52. Maruyama S, Tsukada H, Nishiyama S et al (2008) In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 325:774-781
53. Yoshida A, Fujino T, Maruyama S, Ito Y, Taki Y, Yamada S (2010) The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder. J Pharmacol Sci 112:142-150
54. Callegari E, Webster R, Fenner K, LaPerle J, Malhotra BK, Bungay P (2010) Focused Conference Group: P08 - Developments in the treatment of sexual dysfunction and diseases of the lower urinary tract. Comparison of central nervous system penetration of antimuscarinic drugs for overactive bladder. Basic Clin Pharmacol Toxicol 107(Suppl. 1):162-192
55. Klausner AP, Steers WD (2007) Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Urol Rep 8:441-447
56. Anagnostaras SG, Murphy GG, Hamilton SE et al (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6:51-58
57. Messer WS Jr, Bohnett M, Stibbe J (1990) Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci Lett 116:184-189
58. Kay G, Crook T, Rekeda L et al (2006) Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50:317-326
59. Kay G,Wesnes K (2005) Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 96:1055-1062
60. Lipton RB, kolodner K, Wesnes K (2005) Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 173:493-498
61. Kay G, Kardiasmenos K, Crook T (2006) Differential effects of the antimuscarinic agents tolterodine tartrate and oxybutynin ER on recent memory in older subjects [abstract 87]. Annual Meeting of the International Continence Society, Christchurch, New Zealand. https:// www.icsoffice.org/aspnet- membership/membership/Abstracts/ AbstractsSearch.aspx?EventID=44. Accessed 7 October 2010
62. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J (2009) Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 8:615-626
63. Staskin D, Kay G, Tannenbaum C et al (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64:1294-1300
64. Giramonti KM, Kogan BA, Halpern LF (2008) The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn 27:315-318
65. Nagels G, De Deyn PP, Vleugels L, D'hooghe MB, Van Glabeke I, Van Laere K, and De Ridder D (2004) A prospective randomized double blind cross-over dose-titration study to evaluate the cognitive safety profile of tolterodine as compared to oxybutynin in multiple sclerosis patients with a neurogenic overactive bladder: a planned interim analysis [abstract 237]. Annual Meeting of the International Continence Society, Paris, France. https://www.icsoffice.org/ ASPNET-Membership/Membership/ Abstracts/AbstractsSearch.aspx?EventID=42. Accessed 7 October 2010
66. Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I (2005) Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged >=50 years. BJU Int 95:346-349
67. Tsao JW, Heilman KM (2003) Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 349:2274-2275
68. Salvatore S, Serati M, Cardozo L, Uccella S, Bolis P (2007) Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol 197:e8
69. Womack KB, Heilman KM (2003) Tolterodine and memory: dry but forgetful. Arch Neurol 60:771-773
70. Diefenbach K, Donath F, Maurer A et al (2003) Randomised double-blind study of the effects of oxybutynin tolterodine trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 23:395-404
71. Nye AM, Clinard VB, Barnes CL (2010) Medication nonadherence secondary to drug-induced memory loss. Consult Pharm 25:117-121
72. Gulsun M, Pinar M, Sabanci U (2006) Psychotic disorder induced by oxybutynin: presentation of two cases. Clin Drug Investig 26:603-606
73. Ohtake A, Sato S, Sasamata M, Miyata K (2010) The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. J Pharmacol Sci 112:135-141
74. Maruyama S, Tsukada H, Yamada S (2007) In vivo analysis of brain muscarinic receptor occupancy after oral oxybutynin in conscious rhesus monkey by using positron emission tomography (PET). Neurourol Urodyn 26:703-704
75. US Department of Health and Human Services (2007) Summary Health Statistics for US Adults: National Health Interview Survey, 2007. Centers for Disease Control and Prevention and National Center for Health Statistics, 10
76. Andersson KE, Olshansky B (2007) Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 100:1007-1014
77. Jouven X, Empana JP, Escolano S et al (2009) Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 103:279-283
78. Fox K, Borer JS, Camm AJ et al (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50:823-830
79. Hsia J, Larson JC, Ockene JK et al (2009) Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 338:b219
80. Tsuji H, Venditti FJ Jr, Manders ES et al (1994) Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 90:878-883
81. Tsuji H, Larson MG, Venditti FJ Jr et al (1996) Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 94:2850-2855
82. Colhoun HM, Francis DP, Rubens MB, Underwood SR, Fuller JH (2001) The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: a study in type 1 diabetic patients and the general population. Diabetes Care 24:1108-1114
83. Schiffers M, Sauermann P, Schurch B, Mehnert U (2010) The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 28:651-656
84. Chapple C, Van KP, Tubaro A et al (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52:1204-1212
85. Hozawa A, Ohkubo T, Kikuya M et al (2004) Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama Study. Am J Hypertens 17:1005-1010
86. Dwyer P, Kelleher C, Young J et al (2008) Long-term benefits of darifenacin treatment for patient quality of life: results from a 2- year extension study. Neurourol Urodyn 27:540-547
87. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178